{
    "2019-05-05": [
        [
            {
                "time": "",
                "original_text": "板块分化后的投资策略 ——兴证医药2019年5月投资月报",
                "features": {
                    "keywords": [
                        "板块分化",
                        "投资策略",
                        "兴证医药"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "286家药企一季度成绩单出炉！白云山、恒瑞……净利润超10亿，这9家毛利率超90%",
                "features": {
                    "keywords": [
                        "药企",
                        "一季度",
                        "白云山",
                        "恒瑞",
                        "净利润",
                        "毛利率"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【国盛医药张金洋团队】年报季报验证医药从野蛮扩张到结构优化，继续推荐医药流通",
                "features": {
                    "keywords": [
                        "国盛医药",
                        "年报季报",
                        "野蛮扩张",
                        "结构优化",
                        "医药流通"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "机会来了！巴菲特投资中国或有大动作 哪些标的能入股神法眼？",
                "features": {
                    "keywords": [
                        "巴菲特",
                        "投资中国",
                        "大动作",
                        "标的"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "跨行业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}